Puma Biotech director grants 27K RSUs, sells 8.1K

Puma Biotechnology director Brian M. Stuglik reported both an equity grant and a share sale.

Rhea-AI Filing Summary

Puma Biotechnology director Brian M. Stuglik reported both an equity grant and a share sale. On June 11, 2026, he acquired 27,000 shares of common stock at $0.00 per share as a grant of Restricted Stock Units that vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to continued service. On June 12, 2026, he executed an open-market sale of 8,100 common shares at a weighted average price of $7.1989 per share, in multiple trades between $6.98 and $7.32, under a Rule 10b5-1(c) trading plan adopted on March 12, 2025. Following these transactions, he directly holds 113,858 common shares.

Insider Trade Summary 10b5-1

Net Seller: 8,100 shares

Net Sell 2 txns

Insider Stuglik Brian M

Role Director

Sold 8,100 shs ($58K)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,100	$7.1989	$58K
Grant/Award	Common Stock	27,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 113,858 shares (Direct)

Footnotes (3)

1. F1. Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.
2. F2. Adoption date of referenced 10b5-1(c) plan is: 03-12-2025
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 8,100 shares Weighted average sale price: $7.1989 per share RSU grant size: 27,000 shares +2 more

5 metrics

Shares sold 8,100 shares Open-market sale of common stock on June 12, 2026

Weighted average sale price $7.1989 per share Common stock sale on June 12, 2026; trades $6.98–$7.32

RSU grant size 27,000 shares Restricted Stock Unit grant on June 11, 2026

Post-transaction holdings 113,858 shares Common stock directly owned after reported transactions

10b5-1 plan adoption date March 12, 2025 Plan governing June 12, 2026 share sale

Key Terms

Restricted Stock Units, Rule 10b5-1(c) plan, weighted average price, open-market sale

4 terms

Restricted Stock Units financial

"Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1(c) plan regulatory

"Adoption date of referenced 10b5-1(c) plan is: 03-12-2025"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did PBYI director Brian Stuglik report?

Brian M. Stuglik reported a stock grant and a sale. He received 27,000 Puma Biotechnology common shares as a Restricted Stock Unit grant, then sold 8,100 shares in the open market at a weighted average price of $7.1989 per share.

How many Puma Biotechnology (PBYI) shares did the director sell and at what price?

He sold 8,100 Puma Biotechnology common shares in an open-market transaction. The weighted average sale price was $7.1989 per share, with individual trades executed between $6.98 and $7.32 per share, according to the disclosed pricing range.

What equity award did PBYI grant to director Brian Stuglik?

Puma Biotechnology granted Brian M. Stuglik 27,000 shares of common stock as Restricted Stock Units at a grant price of $0.00. These RSUs vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting.

When do Brian Stuglik’s Puma Biotechnology RSUs vest?

The Restricted Stock Units vest in full on the earlier of the one-year anniversary of the grant date or the annual shareholder meeting following the grant date. Vesting is conditioned on his continued service with Puma Biotechnology through the applicable vesting date.

Was the PBYI director’s share sale made under a Rule 10b5-1 plan?

Yes. The Form 4 notes that the sale on June 12, 2026 was executed pursuant to a Rule 10b5-1(c) trading plan. The adoption date of this pre-arranged plan is March 12, 2025, indicating the sale was scheduled in advance.

How many Puma Biotechnology (PBYI) shares does Brian Stuglik hold after these transactions?

After the reported grant and sale, Brian M. Stuglik directly holds 113,858 shares of Puma Biotechnology common stock. This post-transaction holding figure reflects the net result of the 27,000-share grant and the 8,100-share open-market sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 08:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stuglik Brian M

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BOULEVARD, SUITE 1700

(Street)

LOS ANGELES CALIFORNIA 90024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		27,000	A	$0(1)	121,958	D
Common Stock	06/12/2026		S(2)		8,100	D	$7.1989(3)	113,858	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.

2. Adoption date of referenced 10b5-1(c) plan is: 03-12-2025

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Gordon Esplin as attorney-in-fact for Brian M. Stuglik	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)